{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:47:27Z","timestamp":1781106447317,"version":"3.54.1"},"reference-count":24,"publisher":"Japanese Society for Pediatric Endocrinology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pediatr Endocrinol"],"published-print":{"date-parts":[[2015]]},"DOI":"10.1297\/cpe.24.37","type":"journal-article","created":{"date-parts":[[2015,5,14]],"date-time":"2015-05-14T18:01:17Z","timestamp":1431626477000},"page":"37-49","source":"Crossref","is-referenced-by-count":21,"title":["Treatment situation of male hypogonadotropic hypogonadism in pediatrics and proposal of testosterone and gonadotropins replacement therapy protocols"],"prefix":"10.1297","volume":"24","author":[{"given":"Naoko","family":"Sato","sequence":"first","affiliation":[{"name":"Tanaka Growth Clinic, Tokyo, Japan"},{"name":"Study Group of Treatment for MHH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonobu","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Keio University Hospital, Tokyo, Japan"},{"name":"Pharmaceutical Affairs Committee, the Japanese Society for Pediatric Endocrinology"},{"name":"Study Group of Treatment for MHH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Tokyo Metropolitan Children\u2019s Medical Center, Tokyo, Japan"},{"name":"Study Group of Treatment for MHH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Arisaka","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan"},{"name":"Pharmaceutical Affairs Committee, the Japanese Society for Pediatric Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Ozono","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Osaka University, Osaka, Japan"},{"name":"Pharmaceutical Affairs Committee, the Japanese Society for Pediatric Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Amemiya","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Saitama Medical University, Saitama, Japan"},{"name":"Pharmaceutical Affairs Committee, the Japanese Society for Pediatric Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Niigata University, Niigata, Japan"},{"name":"Pharmaceutical Affairs Committee, the Japanese Society for Pediatric Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Pharmaceutical Affairs Committee, the Japanese Society for Pediatric Endocrinology"},{"name":"Study Group of Treatment for MHH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Harada","sequence":"additional","affiliation":[{"name":"Division of Clinical Practice Policy, National Institute for Child Health and Development, Tokyo, Japan"},{"name":"Pharmaceutical Affairs Committee, the Japanese Society for Pediatric Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Miyata","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Jikei University School of Medicine, Tokyo, Japan"},{"name":"Pharmaceutical Affairs Committee, the Japanese Society for Pediatric Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Tanaka Growth Clinic, Tokyo, Japan"},{"name":"Pharmaceutical Affairs Committee, the Japanese Society for Pediatric Endocrinology"},{"name":"Study Group of Treatment for MHH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"125","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Han TS, Bouloux PM. What is the optimal therapy for young males with hypogonadotropic hypogonadism? Clin Endocrinol (Oxf) 2010;72: 731\u20137.","DOI":"10.1111\/j.1365-2265.2009.03746.x"},{"key":"2","unstructured":"2. Manual for the diagnosis and treatment of decreased gonadotropin secretion. Investigational research team for functional hypothalamic and pituitary disorders, research on measures for intractable diseases. Health and labor sciences research grant (http:\/\/rhhd.info\/) (Only in Japanese)."},{"key":"3","unstructured":"3. Oyama K, Nakagome Y, Kobayashi H, Satoh K, Uchida N, Sano T, et al. Examination of methods for inducing secondary sex characteristics for the treatment of male hypogonadotropic hypogonadism. Jap J Pediatr Soc 2008;112: 1667\u201373 (Only in Japanese)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Rogol AD. New facets of androgen replacement therapy during childhood and adolescence. Expert Opin Pharmacother 2005;6: 1319\u201336.","DOI":"10.1517\/14656566.6.8.1319"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nabhan Z, Eugster EA. Hormone replacement therapy in children with hypogonadotropic hypogonadism: where do we stand? Endocr Pract 2013;19: 968\u201371.","DOI":"10.4158\/EP13101.OR"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Drobac S, Rubin K, Rogol AD, Rosenfield RL. A workshop on pubertal hormone replacement options in the United States. J Pediatr Endocrinol Metab 2006;19: 55\u201364.","DOI":"10.1515\/JPEM.2006.19.1.55"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Shiraishi K, Oka S, Matsuyama H. Assessment of quality of life during gonadotrophin treatment for male hypogonadotrophic hypogonadism. Clin Endocrinol (Oxf) 2014;81: 259\u201365.","DOI":"10.1111\/cen.12435"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Bergad\u00e1 I, Bergad\u00e1 C. Long term treatment with low dose testosterone in constitutional delay of growth and puberty: effect on bone age maturation and pubertal progression. J Pediatr Endocrinol Metab 1995;8: 117\u201322.","DOI":"10.1515\/JPEM.1995.8.2.117"},{"key":"9","unstructured":"9. Tanaka T, Suwa S, Yokoya S, Hibi I. Analysis of linear growth during puberty. Acta Paediatr Scand Suppl 1988;347: 25\u20139 [Suppl]."},{"key":"10","unstructured":"10. Tanaka T. Pubertal growth and maturation in healthy girls. J Jpn Ass Hum Auxo 2006;12: 3\u20139 (Only in Japanese)."},{"key":"11","unstructured":"11. MacGillivray MH. Induction of puberty in hypogonadal children. J Pediatr Endocrinol Metab 2004;17(Suppl 4): 1277\u201387."},{"key":"12","unstructured":"12. Isolated Gonadotropin-Releasing Hormone (GnRH) Deficiency Buck C, Balasubramanian R, Crowley WF. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K, editors. GeneReviews\u2122 [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2013. 2007 May 23 [updated 2013 Jul 18]."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Anderson RA, Kelly RW, Wu FC. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. V. Localization of higher 5 alpha-reductase activity to the reproductive tract in oligozoospermic men administered supraphysiological doses of testosterone. J Androl 1997;18: 366\u201371.","DOI":"10.1002\/j.1939-4640.1997.tb01940.x"},{"key":"14","unstructured":"14. Wallace EM, Gow SM, Wu FC. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations. J Clin Endocrinol Metab 1993;77: 290\u20133."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kim ED, Crosnoe L, Bar-Chama N, Khera M, Lipshultz LI. The treatment of hypogonadism in\u00a0men of reproductive age. Fertil Steril 2013;99: 718\u201324.","DOI":"10.1016\/j.fertnstert.2012.10.052"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Moss JL, Crosnoe LE, Kim ED. Effect of rejuvenation hormones on spermatogenesis. Fertil Steril 2013;99: 1814\u201320.","DOI":"10.1016\/j.fertnstert.2013.04.003"},{"key":"17","unstructured":"17. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag 2009;5: 427\u201348."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Zacharin M, Sabin MA, Nair VV, Dabadghao P. Addition of recombinant follicle-stimulating hormone to human chorionic gonadotropin treatment in adolescents and young adults with hypogonadotropic hypogonadism promotes normal testicular growth and may promote early spermatogenesis. Fertil Steril 2012;98: 836\u201342.","DOI":"10.1016\/j.fertnstert.2012.06.022"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Dwyer AA, Sykiotis GP, Hayes FJ, Boepple PA, Lee H, Loughlin KR, et al. Trial of recombinant follicle-stimulating hormone pretreatment for GnRH-induced fertility in patients with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2013;98: E1790\u20135.","DOI":"10.1210\/jc.2013-2518"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Raivio T, Wikstr\u00f6m AM, Dunkel L. Treatment of gonadotropin-deficient boys with recombinant human FSH: long-term observation and outcome. Eur J Endocrinol 2007;156: 105\u201311.","DOI":"10.1530\/eje.1.02315"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Young J, Chanson P, Salenave S, No\u00ebl M, Brailly S, O\u2019Flaherty M, et al. Testicular anti-mullerian hormone secretion is stimulated by recombinant human FSH in patients with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2005;90: 724\u20138.","DOI":"10.1210\/jc.2004-0542"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Aydogan U, Aydogdu A, Akbulut H, Sonmez A, Yuksel S, Basaran Y, et al. Increased frequency of anxiety, depression, quality of life and sexual life in young hypogonadotropic hypogonadal males and impacts of testosterone replacement therapy on these conditions. Endocr J 2012;59: 1099\u2013105.","DOI":"10.1507\/endocrj.EJ12-0134"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Romerius P, St\u00e5hl O, Mo\u00ebll C, Relander T, Cavallin-St\u00e5hl E, Wiebe T, et al. Hypogonadism risk in men treated for childhood cancer. J Clin Endocrinol Metab 2009;94: 4180\u20136.","DOI":"10.1210\/jc.2009-0337"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Delemarre-van de Waal HA. Application of gonadotropin releasing hormone in hypogonadotropic hypogonadism\u2014diagnostic and therapeutic aspects. Eur J Endocrinol 2004;151(Suppl 3): U89\u201394.","DOI":"10.1530\/eje.0.151U089"}],"container-title":["Clinical Pediatric Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpe\/24\/2\/24_9995\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T20:03:47Z","timestamp":1717877027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpe\/24\/2\/24_9995\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1297\/cpe.24.37","relation":{},"ISSN":["0918-5739","1347-7358"],"issn-type":[{"value":"0918-5739","type":"print"},{"value":"1347-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}